Thomas F. Lüscher/LinkedIn
Aug 5, 2026, 14:25
Thomas F. Lüscher: ZEUS Trial Highlights the Challenge of Translating Anti-Inflammatory Effects into Clinical Benefit
Thomas F. Lüscher, Director of Research, Education and Development and Consultant of Cardiology at Royal Brompton and Harefield Hospitals, shared a post on LinkedIn:
“ZEUS has been angry: Ziltivekimab reduced IL-6 and hsCRP, but did not translate into MACE risk reduction versus placebo in patients with ASCVD, CKD and inflammation (HR 0.99; CI 0.88-1.11) – will Artemis (AMI) and Hermes (HfpEF) be in better mood?
It is important to continue with these trials as CKD patients may be different, too late in the course of CVD to make a difference with IL-6 blockade.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week